SCHEMBL34461945

CC(C)[C@H](NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1)NC(=O)OC(C)(C)C)[C@@H](C)OC(C)(C)C)[C@@H](C)OC(C)(C)C)C(=O)N[C@@H](COC(C)(C)C)C(=O)N[C@@H](COC(C)(C)C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	REN	P00797	10/20	0.40

▸	BACE1	P56817	3/20	0.37

▸	OPRD1	P41143	5/20	0.36

▸	CCKAR	P32238	4/20	0.36

▸	CCKBR	P32239	4/20	0.36

▸	CASP3	P42574	1/20	0.36

▸	CTSD	P07339	1/20	0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30437059	0.97	REN (0.39)	RENBACE1OPRD1CCKARCCKBR
SCHEMBL34461946	0.97	REN (0.39)	RENOPRD1CCKARCCKBR
SCHEMBL31084236	0.94	BACE1 (0.38)	BACE1OPRD1CCKARCCKBRCTSD
SCHEMBL30524338	0.94	PSEN1 (0.38)	RENOPRD1CASP3CTSD
SCHEMBL30175807	0.92	REN (0.39)	RENBACE1OPRD1
SCHEMBL30437554	0.92	PSEN1 (0.37)	RENOPRD1CASP3CTSD
SCHEMBL31614440	0.92	REN (0.41)	RENOPRD1CCKARCCKBR
SCHEMBL30343346	0.91	PSEN1 (0.36)	RENOPRD1
SCHEMBL30524340	0.90	PSEN1 (0.37)	RENOPRD1
SCHEMBL30437952	0.89	REN (0.40)	RENBACE1OPRD1CCKARCCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12600759-B2	Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs	ENZENE BIOSCIENCES LIMITED (IN)	2026-04-14	—	—	US	claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12600759-B2	Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs	GLP1R, GIPR, GCG	REN 1411/4885BACE1 776/4885OPRD1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.